Crinetics Pharmaceuticals(CRNX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company recognized $6.2 million in total net revenue, comprising $5.4 million from the U.S. launch of PALSONIFY and $0.8 million from a licensing agreement with SKK in Japan [25] - Total revenue for the full year 2025 was $7.7 million, with a cost of product revenue of $1.1 million in Q4 [25][26] - The company ended 2025 with over $1 billion in cash equivalents and investments, excluding $380 million from a public offering in January 2026, bringing total cash to approximately $1.4 billion post-offering [28] Business Line Data and Key Metrics Changes - The launch of PALSONIFY has seen over 200 enrollment forms received in Q4, with more than 125 unique prescribers involved [8][9] - The company is focusing on building a commercial enterprise around PALSONIFY, with a fully integrated team in place to support its launch [10][11] Market Data and Key Metrics Changes - The company is experiencing encouraging formulary momentum with payers, securing wins with top plans in the U.S. for PALSONIFY [9] - Approximately 50% of claims have been pre-reimbursed, with 60% moving into the QuickStart program [63] Company Strategy and Development Direction - Crinetics is transitioning from building a pipeline to establishing a commercial business, aiming to become a leading endocrinology company [7] - The company is focused on launching multiple innovative pharmaceuticals from its pipeline, including paltusotine and atumelnant, while also advancing its nonpeptide drug conjugate program [11][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, highlighting the successful launch of PALSONIFY and ongoing clinical trials for other products [31] - The company is committed to transforming the lives of patients with endocrine diseases and creating long-term sustainable value for stakeholders [31] Other Important Information - The company expects GAAP operating expenses for 2026 to be between $600 million and $650 million, reflecting ongoing investments in clinical trials and commercialization activities [29] - The anticipated increase in operating expenses is due to a full year of commercialization activities supporting PALSONIFY [29] Q&A Session Summary Question: Insights from Phase 2/3 design and previous studies - Management indicated that the structure of the Cushing's disease study is well established, with normalization of urine-free cortisol as a primary endpoint [36][68] Question: Trends in PALSONIFY prescriptions - Management noted positive feedback from prescribers and patients, but refrained from providing specific quantitative trends for the quarter [41][44] Question: Enrollment forms and commercial therapy timeline - Management stated that it is premature to extrapolate the 200 enrollment forms as a consistent run rate, with 50% of patients reimbursed and the other 50% on QuickStart [49][50] Question: Payer dynamics for PALSONIFY - Management reported no significant barriers to treatment access, with most coverage based on labels and a commitment to expedite the QuickStart process [63] Question: ADCS study design and endpoints - Management confirmed that the primary endpoint for the phase 3 study is set by the FDA, focusing on the percentage of patients achieving normal urine-free cortisol [68]